Samsung Biologics, a leading name in the contract development and manufacturing (CDMO) industry, has revealed a landmark collaboration with a European pharmaceutical company through a series of key manufacturing agreements. These deals, valued at over $668 million, will extend through December 2031, further solidifying the company’s reputation as a trusted industry partner.
Thanks to these agreements, Samsung Biologics has surpassed $4 billion in cumulative contract value for 2024 alone. This milestone highlights the company’s dedication to fostering long-term partnerships and delivering high-quality biopharmaceutical solutions to patients worldwide.
John Rim, Chairman and CEO of Samsung Biologics, stated, “We are pleased to deepen our partnership with this European pharmaceutical company, aligning with our shared mission of providing top-tier biologics to patients globally. By investing in cutting-edge technologies and expanding our manufacturing capabilities, we aim to uphold the highest service standards while strengthening customer trust.”
This year, Samsung Biologics has actively expanded its client base, securing partnerships with 17 of the world’s top 20 pharmaceutical companies and broadening its reach across the US, Asia, and Europe. The company has also renewed and expanded contracts with existing clients to support the development of innovative therapies.
Looking ahead, Samsung Biologics plans to enhance its service portfolio by introducing Antibody-Drug Conjugate (ADC) capabilities, supported by a new facility set to be completed by the end of the year. This facility will provide end-to-end ADC services, including process development and conjugation, leveraging the company’s expertise in biologics and antibody engineering.
Further underscoring its commitment to growth, Samsung Biologics is gearing up to launch Bio Campus II next year, with Plant 5 scheduled to start operations in April 2025. These advancements demonstrate the company’s dedication to meeting evolving customer needs and maintaining its leadership in the biopharmaceutical manufacturing sector.